Odyssey Therapeutics' OD-001 meets primary endpoint in Phase 2a ulcerative colitis trial

• Odyssey Therapeutics presented completed Phase 2a induction results for oral OD-001 in moderate-to-severe ulcerative colitis at UEG Week on Oct. 20, 2026.
• The trial met its primary efficacy endpoint, with improvements in symptoms and inflammatory markers supporting continued development.
• OD-001 was generally well tolerated, with no serious adverse events or treatment-related discontinuations during induction.
• The open-label study had no concurrent placebo control, limiting interpretation of the findings.
• Randomized Phase 2b monotherapy and Phase 2a vedolizumab combination trials are planned, with topline induction results expected in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200700PRIMZONEFULLFEED9848944) on October 20, 2026, and is solely responsible for the information contained therein.